Form 4: UTHR CEO Exercises Options, Sells Shares Under 10b5-1 Plan

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock as part of a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), executed transactions on September 9, 2025.
• Exercised 8,000 stock options at an exercise price of $120.26 per share.
• Sold 6,165 shares of common stock at a weighted average price of $398.285 per share.
• Sold an additional 1,835 shares of common stock at a weighted average price of $399.4263 per share.
• These transactions were conducted pursuant to a pre-arranged 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• Following these transactions, direct beneficial ownership of common stock is 130 shares.
• Indirect beneficial ownership of common stock totals 644,359 shares, held by spouse and various family trusts.
• Remaining derivative securities (stock options) beneficially owned directly total 286,000.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, it's a routine, pre-planned transaction under a 10b5-1 plan, which is a positive governance practice. The executive is also realizing a significant profit from the options, which is a positive for the individual.

Positives

• The executive successfully monetized stock options at a significantly higher market price ($398.285 $399.4263) compared to the exercise price ($120.26), indicating a profitable outcome for the individual.
• The transactions were executed under a pre-arranged 10b5-1 trading plan, which demonstrates adherence to good corporate governance practices by providing transparency and mitigating concerns about opportunistic insider trading.

Negatives

• The sale of shares by a key executive, even if pre-planned, could be perceived by some investors as a lack of confidence, although in this context, it is a routine part of executive compensation and liquidity management.

Future Outlook

The pre-arranged 10b5-1 trading plan, under which these transactions occurred, is scheduled to continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026, or December 31, 2025.

Industry Context

Form 4 filings are standard disclosures for executives of publicly traded companies, detailing changes in their beneficial ownership of company securities. The use of a 10b5-1 plan for such transactions is a common practice among executives to manage personal finances while adhering to insider trading regulations, providing a pre-scheduled, non-discretionary approach to stock sales.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of common stock includes shares held by the reporting person's spouse and various family trusts, some of which the reporting person shares investment power or is a beneficiary/trustee.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding executive compensation and stock ownership changes, which is a routine aspect of public company reporting. The pre-planned nature of the sale under a 10b5-1 plan generally mitigates concerns about market timing.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The 10b5-1 trading plan will continue until the earlier of the exhaustion of 294,000 stock options (expiring March 15, 2026) or December 31, 2025.

Key Dates

Keywords

UTHR, United Therapeutics, Form 4, Insider Trading, Stock Options, Martine Rothblatt, 10b5-1 Plan, Executive Compensation